Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure.
- 1 July 1981
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 3 (4), 456-459
- https://doi.org/10.1161/01.hyp.3.4.456
Abstract
Blood concentration and urinary excretion of captopril following 50 mg oral administration were determined by high-performance liquid chromatography in normal subjects and patients with chronic renal failure. In normal subjects, the maximum blood concentration of the free form of captopril was obtained within 1 hour and was not detectable after 6 hours; 41% of administered captopril was excreted into the urine as free form and metabolites within 2 hours, and 58% within 6 hours. In chronic renal failure patients with an average serum creatinine of 5.1 mg/dl, the absorption constant (Ka), maximum concentration (Cmax), and area under the blood concentration curve (AUC) were not significantly different from those in the normal subjects, but the elimination constant (Ke) and biological half-life (T1/2) showed a significant delay in the disappearance of captopril from the blood (p less than 0.01 respectively). The cumulative amount of urinary excretion of either free-form captopril or its' metabolites was significantly decreased at 2, 4, and 6 hours in chronic renal failure patients (p less than 0.01 or less, respectively). Impairment of kidney function is suggested to be an important factor in the promotion of blood retention of captopril.This publication has 8 references indexed in Scilit:
- Determination of captopril in blood and urine by high-performance liquid chromatography.CHEMICAL & PHARMACEUTICAL BULLETIN, 1981
- Disposition of captopril in normal subjectsClinical Pharmacology & Therapeutics, 1980
- Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive PatientsAnnals of Internal Medicine, 1979
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patientsProgress in Cardiovascular Diseases, 1978
- Haemodynamics of Orally-Active Converting Enzyme Inhibitor (SQ 14225) in Hypertensive PatientsClinical Science, 1978
- INNAPPROPRIATE RENIN SECRETION UNMASKED BY CAPTOPRIL (SQ 14 225) IN HYPERTENSION OF CHRONIC RENAL FAILUREThe Lancet, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978